Clinical Trial Update: Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease [Phase 2]

View source ↗

Summary

This Phase 2 trial update evaluates acalabrutinib for chronic graft-versus-host disease. The study is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematopoietic and Lymphoid Cell Neoplasm

Drugs mentioned

• Acalabrutinib (acalabrutinib)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING